Emergency Care Partners finalizes its merger with Chicago’s IEMS
Category: #health  By Pankaj Singh  Date: 2019-09-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Emergency Care Partners finalizes its merger with Chicago’s IEMS

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which makes them the go-to place for treating diseases and injuries.

Emergency Care Partners (ECP) is one such provider of outsourced emergency department management services and emergency medicine to medical facilities around New York, Pennsylvania and Louisiana. The company has recently finalized its strategic merger with IEMS (Illinois Emergency Medicine Specialists), a medical group that offers outsourced emergency department management services.

Speaking on the move, Bill Yarbrough, CEO, Emergency Care Partners, said that the company is thrilled to accept IEMS as a group member. Moreover, the strength of IEMS’s local health system relationships and its vast experience as physician partners makes it the perfect addition to their company’s national group.

Reportedly, the newly formed emergency medicine service will offer departmental operations at 26 clinics and hospitals, along with a shared clinical staff of 600 mid-level providers and physicians, handling an estimate of 900,000 ER patient visits yearly.

Sources cite that IEMS’s physician partners will also join ECP shareholders along with Ted Patras, M.D., who will stay as the President of the Chicago based emergency medicine specialist.

Incidentally, the U.S. healthcare sector is witnessing numerous mergers lately. For instance, recently WellNow Urgent Care, a New York-based leading providers of urgent care, ventured with St. Peter's Health Partners that would add both the firms name on two WellNow’s operations and six operating locations handled by St. Peter's in the Capital Region.

Reportedly, WellNow's Hudson and Niskayuna facilities will be the initial places that would be redesigned as co-branded facilities. The centers will be open 24/7 and will not need any prior appointments.

Moreover, they would have professional medical personnel that would treat non-life-threatening illnesses and injuries like abrasions, burns, coughs, dehydration, sprains, colds, strains and several other cases.

As for the merger with ECP, Dr. Ted Patras, M.D., President, IEMS, said that their company is delighted with the opportunities to join with ECP’s team as the new partnership would enable it to provide the best patient experiences and quality outcomes, and to bring enhanced efficiencies for the complete health system.

Source Credit: https://finance.yahoo.com/news/emergency-care-partners-joins-illinois-180000744.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...